These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31928732)

  • 1. Misfolded proteins as a therapeutic target in Alzheimer's disease.
    Liyanage SI; Weaver DF
    Adv Protein Chem Struct Biol; 2019; 118():371-411. PubMed ID: 31928732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Untangling amyloid-β, tau, and metals in Alzheimer's disease.
    Savelieff MG; Lee S; Liu Y; Lim MH
    ACS Chem Biol; 2013 May; 8(5):856-65. PubMed ID: 23506614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging Proof of Protein Misfolding and Interactions in Multifactorial Alzheimer's Disease.
    Uddin MS; Al Mamun A; Rahman MA; Behl T; Perveen A; Hafeez A; Bin-Jumah MN; Abdel-Daim MM; Ashraf GM
    Curr Top Med Chem; 2020; 20(26):2380-2390. PubMed ID: 32479244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Key Peptides and Proteins in Alzheimer's Disease.
    Penke B; Bogár F; Paragi G; Gera J; Fülöp L
    Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer disease: a tale of two prions.
    Nussbaum JM; Seward ME; Bloom GS
    Prion; 2013; 7(1):14-9. PubMed ID: 22965142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease.
    Barage SH; Sonawane KD
    Neuropeptides; 2015 Aug; 52():1-18. PubMed ID: 26149638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Abnormal Tau Phosphorylation for Alzheimer's Therapeutics.
    Singh A; Ansari VA; Mahmood T; Hasan SM; Wasim R; Maheshwari S; Akhtar J; Sheikh S; Vishwakarma VK
    Horm Metab Res; 2024 Jul; 56(7):482-488. PubMed ID: 38350636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A standard model of Alzheimer's disease?
    Walker LC; Lynn DG; Chernoff YO
    Prion; 2018; 12(5-6):261-265. PubMed ID: 30220236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular interaction between type 2 diabetes and Alzheimer's disease through cross-seeding of protein misfolding.
    Moreno-Gonzalez I; Edwards Iii G; Salvadores N; Shahnawaz M; Diaz-Espinoza R; Soto C
    Mol Psychiatry; 2017 Sep; 22(9):1327-1334. PubMed ID: 28044060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer's disease.
    Jazvinšćak Jembrek M; Slade N; Hof PR; Šimić G
    Prog Neurobiol; 2018 Sep; 168():104-127. PubMed ID: 29733887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's disease as oligomeropathy.
    Ono K
    Neurochem Int; 2018 Oct; 119():57-70. PubMed ID: 28821400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.
    Panza F; Solfrizzi V; Frisardi V; Imbimbo BP; Capurso C; D'Introno A; Colacicco AM; Seripa D; Vendemiale G; Capurso A; Pilotto A
    Aging Clin Exp Res; 2009 Dec; 21(6):386-406. PubMed ID: 20154508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer's Disease.
    Reddy PH; Oliver DM
    Cells; 2019 May; 8(5):. PubMed ID: 31121890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ebselen ameliorates β-amyloid pathology, tau pathology, and cognitive impairment in triple-transgenic Alzheimer's disease mice.
    Xie Y; Tan Y; Zheng Y; Du X; Liu Q
    J Biol Inorg Chem; 2017 Aug; 22(6):851-865. PubMed ID: 28502066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.
    Xin SH; Tan L; Cao X; Yu JT; Tan L
    Neurotox Res; 2018 Oct; 34(3):733-748. PubMed ID: 29626319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenylpropanoids and Alzheimer's disease: A potential therapeutic platform.
    Kolaj I; Imindu Liyanage S; Weaver DF
    Neurochem Int; 2018 Nov; 120():99-111. PubMed ID: 30098379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Insight into the Protein Aggregation in Alzheimer's Disease and its Inhibition.
    Khan AB; Khan RH
    Protein Pept Lett; 2023; 30(11):900-912. PubMed ID: 37953619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synaptic Impairment in Alzheimer's Disease: A Dysregulated Symphony.
    Forner S; Baglietto-Vargas D; Martini AC; Trujillo-Estrada L; LaFerla FM
    Trends Neurosci; 2017 Jun; 40(6):347-357. PubMed ID: 28494972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid-β and Tau in Alzheimer's Disease: Novel Pathomechanisms and Non-Pharmacological Treatment Strategies.
    Nisbet RM; Götz J
    J Alzheimers Dis; 2018; 64(s1):S517-S527. PubMed ID: 29562514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.